<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519854</url>
  </required_header>
  <id_info>
    <org_study_id>P05940</org_study_id>
    <secondary_id>MK-8616-020</secondary_id>
    <secondary_id>19.4.202</secondary_id>
    <nct_id>NCT03519854</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).</brief_title>
  <official_title>A Multi-center, Randomized, Assessor-blinded, Placebo Controlled, Phase II, Parallel Dose-finding Trial in Male Subjects of ASA 1-2 to Assess the Efficacy, Safety and Pharmacokinetics of 5 Doses of Org 25969 When Administered After 0.6 mg.Kg-1 Esmeron® at 3, 5 or 15 Minutes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy, safety, and pharmacokinetics of sugammadex (Org 25969;
      MK-8616) when administered for the reversal of neuromuscular blockade in male participants
      receiving surgery, classified as American Society of Anesthesiologists (ASA) class 1
      (otherwise normal, healthy participant) to class 2 (participant with mild systemic disease).
      The primary objective of this study is to explore the dose-response relation of sugammadex
      given as a reversal agent at 3, 5, or 15 minutes following administration of 0.6 mg/kg
      Esmeron®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2002</start_date>
  <completion_date type="Actual">June 1, 2003</completion_date>
  <primary_completion_date type="Actual">June 1, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9</measure>
    <time_frame>Up to 70 minutes following administration of study treatment</time_frame>
    <description>Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units &quot;minutes:seconds&quot; (mm:ss), was reformatted to be presented in the single unit of &quot;minutes&quot; (min).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Heart Rate at Baseline</measure>
    <time_frame>Up to 45 minutes prior to study treatment administration</time_frame>
    <description>Mean heart rate at baseline was assessed. Baseline heart rate was defined as the heart rate measured under stable anesthesia prior to administration of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Heart Rate at 2 Minutes Following Administration of Study Treatment</measure>
    <time_frame>2 minutes following administration of study treatment</time_frame>
    <description>Mean heart rate at 2 minutes following administration of study treatment was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Heart Rate at 30 Minutes Following Administration of Study Treatment</measure>
    <time_frame>30 minutes following administration of study treatment</time_frame>
    <description>Mean heart rate at 30 minutes following administration of study treatment was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corrected QT Interval (QTc) at Baseline</measure>
    <time_frame>Up to 45 minutes prior to study treatment administration</time_frame>
    <description>Mean QTc interval at baseline was assessed. Baseline QTc interval was defined as the QTc interval measured under stable anesthesia prior to administration of study treatment. The baseline QTc interval is corrected for participant heart rate at baseline prior to study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment</measure>
    <time_frame>2 minutes following administration of study treatment</time_frame>
    <description>Mean QTc interval at 2 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 2 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment</measure>
    <time_frame>30 minutes following administration of study treatment</time_frame>
    <description>Mean QTc interval at 30 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 30 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event</measure>
    <time_frame>Up to 7 days following administration of study treatment</time_frame>
    <description>The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Arm A. Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G. Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm M. Placebo; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).</description>
    <arm_group_label>Arm A. Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm G. Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm M. Placebo; given 15 minutes after Esmeron®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.</description>
    <arm_group_label>Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <other_name>Org 25969; MK-8616; Bridion®.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmeron®</intervention_name>
    <description>Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.</description>
    <arm_group_label>Arm A. Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm G. Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm M. Placebo; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®</arm_group_label>
    <other_name>Rocuronium bromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of ASA class 1 to 2.

          -  Participants scheduled for surgical procedures with an anticipated duration of
             anesthesia of at least 75 minutes, without further need for muscle relaxation other
             than for intubation.

        Exclusion Criteria:

          -  Participants in whom a difficult intubation because of anatomical malformations is
             expected.

          -  Participants known or suspected to have neuromuscular disorders and/or significant
             hepatic or renal dysfunction.

          -  Participants known or suspected to have a (family) history of malignant hyperthermia.

          -  Participants known or suspected to have an allergy to narcotics, muscle relaxants or
             other medication used during general anesthesia.

          -  Participants receiving medication known to interfere with neuromuscular blocking
             agents such as anticonvulsants, aminoglycosides, and Mg^2+.

          -  Participants who have already participated in this trial.

          -  Participants who have participated in another clinical trial, not pre-approved by NV
             Organon, within 30 days of entering into this trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <results_first_submitted>August 28, 2018</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the N=99 randomized participants, N=98 received treatment. Treated participants are counted as Started in the arm that most accurately describes the treatment received. If no treatment was received (N=1 participant), participants are counted as Started in the arm to which they were randomized.</recruitment_details>
      <pre_assignment_details>One participant originally randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. As a result, this participant is counted as Started/Treated in the “Arm A. Placebo; given 3 minutes after Esmeron®” arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
          <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P2">
          <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P3">
          <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P4">
          <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P5">
          <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P6">
          <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P7">
          <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
          <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P8">
          <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P9">
          <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P10">
          <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P11">
          <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P12">
          <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P13">
          <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
          <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P14">
          <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P15">
          <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P16">
          <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P17">
          <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="P18">
          <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">N=3 randomized to Arm A. An additional N=1 (randomized to Arm C) is counted as Started in Arm A</participants>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="4">N=1 (randomized to Arm C) received placebo, 3 min after 1.2 mg/kg Esmeron®</participants>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Technical Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
          <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B2">
          <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B3">
          <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B4">
          <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B5">
          <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B6">
          <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B7">
          <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
          <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B8">
          <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B9">
          <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B10">
          <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B11">
          <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B12">
          <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B13">
          <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
          <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B14">
          <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B15">
          <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B16">
          <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B17">
          <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B18">
          <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="3"/>
            <count group_id="B14" value="6"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="6"/>
            <count group_id="B17" value="6"/>
            <count group_id="B18" value="6"/>
            <count group_id="B19" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="12.1"/>
                    <measurement group_id="B2" value="35.5" spread="14.0"/>
                    <measurement group_id="B3" value="35.8" spread="16.2"/>
                    <measurement group_id="B4" value="41.3" spread="11.6"/>
                    <measurement group_id="B5" value="34.3" spread="9.3"/>
                    <measurement group_id="B6" value="39.0" spread="7.7"/>
                    <measurement group_id="B7" value="38.7" spread="18.6"/>
                    <measurement group_id="B8" value="35.0" spread="11.5"/>
                    <measurement group_id="B9" value="40.5" spread="12.4"/>
                    <measurement group_id="B10" value="40.8" spread="8.4"/>
                    <measurement group_id="B11" value="38.7" spread="11.9"/>
                    <measurement group_id="B12" value="31.5" spread="11.8"/>
                    <measurement group_id="B13" value="33.0" spread="5.6"/>
                    <measurement group_id="B14" value="48.3" spread="11.6"/>
                    <measurement group_id="B15" value="39.8" spread="17.2"/>
                    <measurement group_id="B16" value="41.7" spread="13.6"/>
                    <measurement group_id="B17" value="36.0" spread="12.1"/>
                    <measurement group_id="B18" value="40.2" spread="15.8"/>
                    <measurement group_id="B19" value="38.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="6"/>
                    <measurement group_id="B19" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9</title>
        <description>Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units &quot;minutes:seconds&quot; (mm:ss), was reformatted to be presented in the single unit of &quot;minutes&quot; (min).</description>
        <time_frame>Up to 70 minutes following administration of study treatment</time_frame>
        <population>Per protocol, includes all randomized participants receiving study treatment without major protocol violations, having data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9</title>
          <description>Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units &quot;minutes:seconds&quot; (mm:ss), was reformatted to be presented in the single unit of &quot;minutes&quot; (min).</description>
          <population>Per protocol, includes all randomized participants receiving study treatment without major protocol violations, having data available for this outcome measure.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.05" spread="8.77"/>
                    <measurement group_id="O2" value="22.73" spread="11.58"/>
                    <measurement group_id="O3" value="4.93" spread="1.25"/>
                    <measurement group_id="O4" value="6.25" spread="9.00"/>
                    <measurement group_id="O5" value="1.85" spread="0.62"/>
                    <measurement group_id="O6" value="1.83" spread="0.87"/>
                    <measurement group_id="O7" value="51.67" spread="13.13"/>
                    <measurement group_id="O8" value="27.35" spread="6.35"/>
                    <measurement group_id="O9" value="8.88" spread="7.80"/>
                    <measurement group_id="O10" value="2.28" spread="0.73"/>
                    <measurement group_id="O11" value="2.13" spread="0.93"/>
                    <measurement group_id="O12" value="1.45" spread="0.60"/>
                    <measurement group_id="O13" value="35.58" spread="9.05"/>
                    <measurement group_id="O14" value="6.53" spread="1.73"/>
                    <measurement group_id="O15" value="2.73" spread="0.72"/>
                    <measurement group_id="O16" value="2.05" spread="1.18"/>
                    <measurement group_id="O17" value="2.08" spread="1.97"/>
                    <measurement group_id="O18" value="1.35" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heart Rate at Baseline</title>
        <description>Mean heart rate at baseline was assessed. Baseline heart rate was defined as the heart rate measured under stable anesthesia prior to administration of study treatment.</description>
        <time_frame>Up to 45 minutes prior to study treatment administration</time_frame>
        <population>All randomized participants receiving study treatment, having data available at baseline prior to administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heart Rate at Baseline</title>
          <description>Mean heart rate at baseline was assessed. Baseline heart rate was defined as the heart rate measured under stable anesthesia prior to administration of study treatment.</description>
          <population>All randomized participants receiving study treatment, having data available at baseline prior to administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="3.6"/>
                    <measurement group_id="O2" value="62.0" spread="4.6"/>
                    <measurement group_id="O3" value="63.5" spread="3.9"/>
                    <measurement group_id="O4" value="68.0" spread="11.4"/>
                    <measurement group_id="O5" value="68.2" spread="10.8"/>
                    <measurement group_id="O6" value="69.8" spread="18.5"/>
                    <measurement group_id="O7" value="68.0" spread="10.6"/>
                    <measurement group_id="O8" value="56.7" spread="10.9"/>
                    <measurement group_id="O9" value="64.2" spread="10.5"/>
                    <measurement group_id="O10" value="64.7" spread="7.2"/>
                    <measurement group_id="O11" value="69.7" spread="21.0"/>
                    <measurement group_id="O12" value="57.5" spread="4.7"/>
                    <measurement group_id="O13" value="63.0" spread="11.8"/>
                    <measurement group_id="O14" value="62.7" spread="8.8"/>
                    <measurement group_id="O15" value="65.3" spread="13.5"/>
                    <measurement group_id="O16" value="64.2" spread="8.6"/>
                    <measurement group_id="O17" value="66.5" spread="11.7"/>
                    <measurement group_id="O18" value="68.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heart Rate at 2 Minutes Following Administration of Study Treatment</title>
        <description>Mean heart rate at 2 minutes following administration of study treatment was assessed.</description>
        <time_frame>2 minutes following administration of study treatment</time_frame>
        <population>All randomized participants receiving study treatment, having data available at 2 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heart Rate at 2 Minutes Following Administration of Study Treatment</title>
          <description>Mean heart rate at 2 minutes following administration of study treatment was assessed.</description>
          <population>All randomized participants receiving study treatment, having data available at 2 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="2"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="5"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="18.6"/>
                    <measurement group_id="O2" value="73.0" spread="15.0"/>
                    <measurement group_id="O3" value="84.5" spread="12.0"/>
                    <measurement group_id="O4" value="72.7" spread="12.1"/>
                    <measurement group_id="O5" value="86.2" spread="15.5"/>
                    <measurement group_id="O6" value="74.8" spread="17.7"/>
                    <measurement group_id="O7" value="84.0" spread="15.1"/>
                    <measurement group_id="O8" value="61.3" spread="11.2"/>
                    <measurement group_id="O9" value="70.8" spread="13.7"/>
                    <measurement group_id="O10" value="66.2" spread="9.8"/>
                    <measurement group_id="O11" value="69.8" spread="21.3"/>
                    <measurement group_id="O12" value="67.8" spread="10.2"/>
                    <measurement group_id="O13" value="59.0" spread="1.4"/>
                    <measurement group_id="O14" value="71.2" spread="12.9"/>
                    <measurement group_id="O15" value="77.2" spread="16.5"/>
                    <measurement group_id="O16" value="62.8" spread="5.0"/>
                    <measurement group_id="O17" value="65.4" spread="14.7"/>
                    <measurement group_id="O18" value="64.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heart Rate at 30 Minutes Following Administration of Study Treatment</title>
        <description>Mean heart rate at 30 minutes following administration of study treatment was assessed.</description>
        <time_frame>30 minutes following administration of study treatment</time_frame>
        <population>All randomized participants receiving study treatment, having data available at 30 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heart Rate at 30 Minutes Following Administration of Study Treatment</title>
          <description>Mean heart rate at 30 minutes following administration of study treatment was assessed.</description>
          <population>All randomized participants receiving study treatment, having data available at 30 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="8.6"/>
                    <measurement group_id="O2" value="62.0" spread="2.8"/>
                    <measurement group_id="O3" value="72.0" spread="7.8"/>
                    <measurement group_id="O4" value="72.5" spread="9.6"/>
                    <measurement group_id="O5" value="76.7" spread="11.2"/>
                    <measurement group_id="O6" value="66.6" spread="15.2"/>
                    <measurement group_id="O7" value="77.3" spread="9.5"/>
                    <measurement group_id="O8" value="63.0" spread="12.6"/>
                    <measurement group_id="O9" value="69.7" spread="11.4"/>
                    <measurement group_id="O10" value="72.5" spread="17.1"/>
                    <measurement group_id="O11" value="66.5" spread="23.9"/>
                    <measurement group_id="O12" value="60.0" spread="4.0"/>
                    <measurement group_id="O13" value="65.7" spread="16.8"/>
                    <measurement group_id="O14" value="66.8" spread="11.5"/>
                    <measurement group_id="O15" value="65.3" spread="10.8"/>
                    <measurement group_id="O16" value="63.5" spread="7.9"/>
                    <measurement group_id="O17" value="64.7" spread="14.3"/>
                    <measurement group_id="O18" value="66.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corrected QT Interval (QTc) at Baseline</title>
        <description>Mean QTc interval at baseline was assessed. Baseline QTc interval was defined as the QTc interval measured under stable anesthesia prior to administration of study treatment. The baseline QTc interval is corrected for participant heart rate at baseline prior to study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
        <time_frame>Up to 45 minutes prior to study treatment administration</time_frame>
        <population>All randomized participants receiving study treatment, having data available at baseline prior to administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corrected QT Interval (QTc) at Baseline</title>
          <description>Mean QTc interval at baseline was assessed. Baseline QTc interval was defined as the QTc interval measured under stable anesthesia prior to administration of study treatment. The baseline QTc interval is corrected for participant heart rate at baseline prior to study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
          <population>All randomized participants receiving study treatment, having data available at baseline prior to administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418" spread="2.5"/>
                    <measurement group_id="O2" value="396" spread="11.3"/>
                    <measurement group_id="O3" value="418" spread="17.8"/>
                    <measurement group_id="O4" value="404" spread="20.7"/>
                    <measurement group_id="O5" value="417" spread="13.1"/>
                    <measurement group_id="O6" value="416" spread="20.4"/>
                    <measurement group_id="O7" value="400" spread="23.9"/>
                    <measurement group_id="O8" value="415" spread="19.6"/>
                    <measurement group_id="O9" value="405" spread="15.7"/>
                    <measurement group_id="O10" value="416" spread="21.7"/>
                    <measurement group_id="O11" value="408" spread="22.2"/>
                    <measurement group_id="O12" value="411" spread="13.9"/>
                    <measurement group_id="O13" value="392" spread="13.9"/>
                    <measurement group_id="O14" value="410" spread="11.8"/>
                    <measurement group_id="O15" value="398" spread="14.5"/>
                    <measurement group_id="O16" value="398" spread="23.6"/>
                    <measurement group_id="O17" value="398" spread="24.8"/>
                    <measurement group_id="O18" value="406" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment</title>
        <description>Mean QTc interval at 2 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 2 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
        <time_frame>2 minutes following administration of study treatment</time_frame>
        <population>All randomized participants receiving study treatment, having data available at 2 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment</title>
          <description>Mean QTc interval at 2 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 2 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
          <population>All randomized participants receiving study treatment, having data available at 2 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="2"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="5"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="5"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420" spread="13.7"/>
                    <measurement group_id="O2" value="406" spread="11.8"/>
                    <measurement group_id="O3" value="422" spread="17.0"/>
                    <measurement group_id="O4" value="406" spread="24.7"/>
                    <measurement group_id="O5" value="427" spread="10.5"/>
                    <measurement group_id="O6" value="416" spread="14.5"/>
                    <measurement group_id="O7" value="400" spread="27.5"/>
                    <measurement group_id="O8" value="420" spread="16.3"/>
                    <measurement group_id="O9" value="412" spread="16.6"/>
                    <measurement group_id="O10" value="419" spread="20.3"/>
                    <measurement group_id="O11" value="410" spread="24.9"/>
                    <measurement group_id="O12" value="416" spread="20.2"/>
                    <measurement group_id="O13" value="401" spread="4.2"/>
                    <measurement group_id="O14" value="419" spread="15.6"/>
                    <measurement group_id="O15" value="406" spread="12.9"/>
                    <measurement group_id="O16" value="416" spread="26.5"/>
                    <measurement group_id="O17" value="410" spread="31.8"/>
                    <measurement group_id="O18" value="416" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment</title>
        <description>Mean QTc interval at 30 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 30 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
        <time_frame>30 minutes following administration of study treatment</time_frame>
        <population>All randomized participants receiving study treatment, having data available at 30 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment</title>
          <description>Mean QTc interval at 30 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 30 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)^(1/3). RR interval = 60/heart rate.</description>
          <population>All randomized participants receiving study treatment, having data available at 30 minutes following administration of study treatment. One participant randomized to receive 2 mg/kg Sugammadex at 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418" spread="11.6"/>
                    <measurement group_id="O2" value="416" spread="17.6"/>
                    <measurement group_id="O3" value="427" spread="13.2"/>
                    <measurement group_id="O4" value="415" spread="21.7"/>
                    <measurement group_id="O5" value="433" spread="21.6"/>
                    <measurement group_id="O6" value="424" spread="27.0"/>
                    <measurement group_id="O7" value="392" spread="21.1"/>
                    <measurement group_id="O8" value="420" spread="21.3"/>
                    <measurement group_id="O9" value="425" spread="19.6"/>
                    <measurement group_id="O10" value="413" spread="21.9"/>
                    <measurement group_id="O11" value="400" spread="27.4"/>
                    <measurement group_id="O12" value="422" spread="14.4"/>
                    <measurement group_id="O13" value="400" spread="6.8"/>
                    <measurement group_id="O14" value="418" spread="18.5"/>
                    <measurement group_id="O15" value="408" spread="14.6"/>
                    <measurement group_id="O16" value="421" spread="33.8"/>
                    <measurement group_id="O17" value="411" spread="25.3"/>
                    <measurement group_id="O18" value="418" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing an Adverse Event</title>
        <description>The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.</description>
        <time_frame>Up to 7 days following administration of study treatment</time_frame>
        <population>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Placebo; Given 3 Minutes After Esmeron®</title>
            <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O4">
            <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O5">
            <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O6">
            <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O7">
            <title>Arm G. Placebo; Given 5 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O8">
            <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O9">
            <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O10">
            <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O11">
            <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O12">
            <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O13">
            <title>Arm M. Placebo; Given 15 Minutes After Esmeron®</title>
            <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O14">
            <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O15">
            <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O16">
            <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O17">
            <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
          <group group_id="O18">
            <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron®</title>
            <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event</title>
          <description>The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.</description>
          <population>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex, given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
                <count group_id="O18" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="4"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days following administration of study treatment</time_frame>
      <desc>Includes all randomized participants receiving study treatment. One participant randomized to receive 2 mg/kg Sugammadex given 3 minutes after Esmeron® (Arm C), incorrectly received placebo. This participant is counted in the &quot;Arm A. Placebo; given 3 minutes after Esmeron®&quot; arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A. Placebo; Given 3 Minutes After Esmeron</title>
          <description>Placebo (single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E2">
          <title>Arm B. 1 mg/kg Sugammadex; Given 3 Minutes After Esmeron</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E3">
          <title>Arm C. 2 mg/kg Sugammadex; Given 3 Minutes After Esmeron</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E4">
          <title>Arm D. 4 mg/kg Sugammadex; Given 3 Minutes After Esmeron</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E5">
          <title>Arm E. 6 mg/kg Sugammadex; Given 3 Minutes After Esmeron</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E6">
          <title>Arm F. 8 mg/kg Sugammadex; Given 3 Minutes After Esmeron</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E7">
          <title>Arm G. Placebo; Given 5 Minutes After Esmeron</title>
          <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E8">
          <title>Arm H. 1 mg/kg Sugammadex; Given 5 Minutes After Esmeron</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E9">
          <title>Arm I. 2 mg/kg Sugammadex; Given 5 Minutes After Esmeron</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E10">
          <title>Arm J. 4 mg/kg Sugammadex; Given 5 Minutes After Esmeron</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E11">
          <title>Arm K. 6 mg/kg Sugammadex; Given 5 Minutes After Esmeron</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E12">
          <title>Arm L. 8 mg/kg Sugammadex; Given 5 Minutes After Esmeron</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E13">
          <title>Arm M. Placebo; Given 15 Minutes After Esmeron</title>
          <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E14">
          <title>Arm N. 1 mg/kg Sugammadex; Given 15 Minutes After Esmeron</title>
          <description>Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E15">
          <title>Arm O. 2 mg/kg Sugammadex; Given 15 Minutes After Esmeron</title>
          <description>Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E16">
          <title>Arm P. 4 mg/kg Sugammadex; Given 15 Minutes After Esmeron</title>
          <description>Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E17">
          <title>Arm Q. 6 mg/kg Sugammadex; Given 15 Minutes After Esmeron</title>
          <description>Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
        <group group_id="E18">
          <title>Arm R. 8 mg/kg Sugammadex; Given 15 Minutes After Esmeron</title>
          <description>Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Therapeutic response decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bradypnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor recognizes the right of the investigators to publish, but all publications must be based on data validated by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

